Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Azmi Nabulsi, M.D., Chief Operating Officer, will present at the Evercore 2019 HealthCONx Conference on Tuesday, December 3 at 1:35 p.m. EST at the Four Seasons Hotel, Boston.
To access the live webcast and subsequent archived recordings for this presentation, which will be available for 30 days, please visit the Phathom Pharmaceuticals website at www.phathompharma.com.
About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company's website at www.phathompharma.com.
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030
The global market for Laboratory...
Reference is made to Akastor ASA's (OSE: AKAST) announcement dated 18 April 2024 on the arbitration award issued in respect of the DRU contracts. Payment of the principal sums awarded, in total USD 108 million (exclusive interest), has now been...
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...
